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Summary
A novel anti-apoptotic alpha-adrenergic agonist pre-
serves left ventricular ejection fraction in mice following
myocardial infarction. This therapeutic effect is able to
be detected and quantified non-invasively, using T2* sig-
nal loss assessment of an Annexin-SPIO molecular
apoptosis probe.
Background
Myocardial infarction (MI) leads to cardiomyopathy
through a combination of programmed cell death (re:
apoptosis) and necrotic cell death. The relative contribu-
tion of apoptosis to ischemic cardiomyopathy and the
effect of targeting apoptosis specifically to prevent MI-
induced damage is unknown. Our laboratory previously
developed and validated an in vivo, MRI-detectable
apoptosis probe. Annexin-V (ANX), which binds to cells
in the earliest stages of apoptosis, was conjugated to
superparamagnetic iron oxide (SPIO) nanoparticles,
allowing for the non-invasive detection of early apopto-
tic cell populations (ANX-SPIO r1: 8.6 ± 0.61 mM-1 s-1
and r2: 326 ± 16 mM-1 s-1). To test the effect of apop-
tosis reversal in an MI model, we employed A61603
(A6), an a1-adrenergic receptor agonist, which was pre-
viously shown to rescue cardiac cells from Doxorubicin-
induced cardiac apoptosis through activation of the car-
dio-protective ERK pathway. Our hypothesis is that A6
therapy will protect against MI-induced cardiomyopathy,
and that cardiac MRI of systemic ANX-SPIO will detect
and longitudinally monitor this therapeutic effect in
vivo.
Methods
Mice underwent MI (via LAD ligation) along with a
subcutaneous pump implant that delivered A6 or vehicle
(VEH) solution at a rate of 10 ng/kg/day over a course
of two weeks. Cardiac MRI (CMR) was performed at 2
days, 1 week, and 2 weeks post MI. ANX-SPIO was
delivered via tail vein one day prior to CMR to simulta-
neously assess left ventricular function and apoptosis
(using T2* signal loss as a marker of apoptotic activity)
in vivo.
Results
Although A6-treated (39±5%, n=3) and VEH-treated (38
±10%, n=6) mice exhibited identical ejection fractions
(EFs) 2 days post-MI, A6-treated mice exhibited signifi-
cantly (p<0.05) higher ejection fractions (EFs) versus
their VEH-treated counterparts at both 1 week (A6,
n=6: 37±9%; VEH, n=5: 18±4%) and 2 weeks (A6, n=5:
33±10%; VEH, n=6: 14±7%) post-MI (Figure 1). Upon
T2* quantification, A6-treated mice showed significantly
(p<0.05) less T2* signal loss after ANX-SPIO delivery
compared to VEH-treated mice at 1 week post MI (A6
T2*: 19±2ms; VEH T2*: 14±1, n=3), reflecting less myo-
cardial uptake of ANX-SPIO and therefore less cardiac
cell apoptosis in A6-treated hearts (Figure 2).
Conclusions
These results suggest that cardiomyocyte apoptosis is a
prominent contributor to the functional impairment of
ischemic cardiomyopathy and that A6-mediated
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any medium, provided the original work is properly cited.Figure 1 Graph of EFs for A6-treated vs VEH-treated mice over a two week period. Note the significant preservation of EFs in A6-treated hearts
at 1 and 2 weeks.
Figure 2 a) CMR images of an infarcted mouse heart showing T2* signal loss from ANX-SPIO; b) CMR of A6-treated, infarcted mouse heart
showing a visibly reduced degree of T2* signal loss, compared to VEH control hearts; c) T2* signal loss curves for control animals, as well as MI
+A6-treated and MI+VEH hearts. The steeper decay curve of MI+VEH hearts reflects the increased apoptosis and subsequent ANX-SPIO uptake,
compared to A6-treated hearts.
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cardiac function. Moreover, ANX-SPIO can non-inva-
sively detect and monitor A6’s therapeutic effect
longitudinally.
Funding
NIH-NHLBI K08 (RD), R01 (PY).
Author details
1Cardiovascular Medicine, Stanford University, Stanford, CA, USA.
2Cardiac
Surgery, Stanford University Medical Center, Stanford, CA, USA.
3Medicine
and Cardiology, University of California, San Francisco, CA, USA.
4Medicine
and Cardiology, San Francisco VA Medical Center, San Francisco, CA, USA.
Published: 1 February 2012
doi:10.1186/1532-429X-14-S1-P67
Cite this article as: Lam et al.: In vivo detection and treatment of
ischemia-induced cardiac apoptosis using an MRI-detectable molecular
probe and an alpha-adrenergic receptor agonist. Journal of
Cardiovascular Magnetic Resonance 2012 14(Suppl 1):P67.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lam et al. Journal of Cardiovascular Magnetic Resonance 2012, 14(Suppl 1):P67
http://www.jcmr-online.com/content/14/S1/P67
Page 3 of 3